BioScrip, Inc. (NASDAQ:BIOS) was upgraded by stock analysts at SunTrust Banks, Inc. from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, The Fly reports. The brokerage currently has a $3.75 price objective on the stock, up from their prior price objective of $3.25. SunTrust Banks, Inc.’s price target would suggest a potential upside of 29.76% from the company’s current price.

Other research analysts also recently issued research reports about the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $4.00 price target (up previously from $3.00) on shares of BioScrip in a report on Thursday. Barrington Research increased their price target on shares of BioScrip to $3.50 and gave the company an “outperform” rating in a report on Monday, June 26th. ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Zacks Investment Research raised shares of BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Wednesday, July 5th. Finally, BidaskClub downgraded shares of BioScrip from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 1st. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. BioScrip presently has an average rating of “Buy” and a consensus price target of $3.75.

Shares of BioScrip (NASDAQ:BIOS) opened at 2.89 on Thursday. The company’s market cap is $349.64 million. The stock has a 50 day moving average price of $2.81 and a 200-day moving average price of $2.01. BioScrip has a 1-year low of $0.98 and a 1-year high of $3.43.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by $0.01. The company had revenue of $218.11 million for the quarter, compared to analysts’ expectations of $220.05 million. During the same period last year, the firm posted ($0.14) earnings per share. The company’s revenue was down 6.2% compared to the same quarter last year. Equities research analysts forecast that BioScrip will post ($0.38) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was posted by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/bioscrip-inc-bios-upgraded-to-buy-at-suntrust-banks-inc/1468297.html.

Hedge funds have recently made changes to their positions in the company. Benchmark Capital Advisors purchased a new stake in shares of BioScrip during the second quarter valued at about $391,000. Bank of New York Mellon Corp increased its stake in shares of BioScrip by 6.0% in the second quarter. Bank of New York Mellon Corp now owns 504,459 shares of the company’s stock valued at $1,369,000 after buying an additional 28,615 shares during the last quarter. Rhumbline Advisers increased its stake in shares of BioScrip by 9.2% in the second quarter. Rhumbline Advisers now owns 130,122 shares of the company’s stock valued at $353,000 after buying an additional 10,985 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of BioScrip by 0.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 490,698 shares of the company’s stock valued at $1,333,000 after buying an additional 2,622 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC increased its stake in shares of BioScrip by 248.4% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 15,211,136 shares of the company’s stock valued at $41,298,000 after buying an additional 10,845,410 shares during the last quarter. 91.16% of the stock is owned by institutional investors and hedge funds.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

The Fly

Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.